Our Customers
*Customers listed are non objected on disclosure
China Beijing Tongrentang Group Co., Ltd.
Tong Ren Tang was Founded in 1669. It is specialized in traditional Chinese medicine including pharmaceuticals, health and wellness, senior medical care, retail, etc. It has more than 36 pharmaceutical plants in China producing more than 2,600 medicines and dietary supplements, and more than 2,400 retail stores and medical institutions. It has also set up in 28 countries and regions, including USA, Canada, UK, Netherlands, Sweden, Switzerland, etc., many service terminals to provide Chinese medicine services to local people. In 2018, Tong Ren Tang registered a revenue of 2.7 billion USD, and an asset of more than 4.1 billion USD.
China Resources Sanjiu Medical & Pharmaceutical Co., Ltd.
China Resources Sanjiu Medical & Pharmaceutical Co., Ltd. is a large state-owned holding listed pharmaceutical company, mainly engaged in the research and development, production, sales and related health services of pharmaceutical products. The core business of CR Sanjiu is in the field of CHC healthcare products and prescription drugs, with a wide range of product coverage and continued enrichment of product lines and varieties. CHC's consumer healthcare business covers nearly 10 categories, including cold and flu, skin, gastrointestinal, cough, orthopedics, pediatrics, dietary supplements, etc., and its core products occupy a high market share; its prescription business covers anti-tumor, cardiovascular and cerebral vascular, gastrointestinal, orthopedics, pediatrics and other therapeutic areas, and it enjoys a high reputation on the medical side. In 2022, the revenue of CR Sanjiu was 2.58 billion USD.
Sunflower Pharmaceutical Group Co., Ltd.
Sunflower Pharmaceutical Group owns a number of branch companies such as pharmaceutical manufacturing enterprises, pharmaceutical companies, pharmaceutical research institutes, herb cultivation plants, etc. It products cover the fields of pediatrics, gynecology, digestive system, respiratory cold, rheumatic bone disease, cardiovascular and cerebrovascular, including more than 200 Chinese patent medicines, chemical medicines, biological medicines and dietary supplements. Among them, Pediatric Lung-Heat Cough & Asthma Oral Liquid/Particles has been recognized by the China Non-prescription Medicines Association (CNMA) as the "No. 1 in the category of pediatric cold and cough of proprietary Chinese medicines" for many years in a row. In 2022, the revenue of Sunflower Pharmaceutical Group reached 720 million USD, with 500 million came from Chinese patent medicine.
Livzon Pharmaceutical Group Inc.
Livzon Pharmaceutical Group Inc., founded in 1985, is a comprehensive pharmaceutical group company integrating pharmaceutical R&D, manufacturing and sales with more than 8,000 employees. The group currently produces and sells chemical drugs, Chinese patent medicines, biological drugs, and in vitro diagnostic reagents in the fields of digestion, cardiovascular and cerebrovascular, reproductive endocrinology, and psychiatric/ neurological. In 2022, the revenue of the group reached 1.8 billion USD, and 200 million USD investment in R&D.
Dihon Pharmaceutical Group Co., Ltd.
Dihon Pharmaceutical Group Co., Ltd., founded in 1993, is now a subsidiary company of Bayer. It is among Top 10 OTC companies in China. It’s main product is Compound Ketoconazole Ointment for skin problems. Its annual income is about 200 million USD.
Golden Throat Holdings Group Company Limited
Golden Throat Holdings Group Company Limited, founded in 1956, has become one of the Top 50 Chinese patent medicine manufacturers after years of development. The group specializes in the fields of Chinese patent medicines and dietary supplements, and now has more than 60 Chinese patent medicines. The most important product the Golden Throat Lozenge has been exported to more than 50 countries and regions in North America, Europe, and Southeast Asia. In 2022, the revenue of the group was 140 million USD.
Yangtzi River Pharmaceutical Group
Yangztzi River Pharmaceutical Group, founded in 1971, is a Chinese pharmaceutical group listed by Ministry of Science and Technology as one of the first Innovative Enterprises of China and owns more than 16,000 employees. The products cover chemical drugs, Chinese patent medicines, comprehensive health care products, etc. With the group’s effort, 5 international standards for Chinese medicinal materials have entered into European Pharmacopoeia. In addition to China, its products have been also sold to more than 50 other countries and regions. In 2022, the revenue of Yangtzi River was more than 11 billion USD.
Beihai Gofar Chuanshan Biological Co., Ltd.
Beihai Gofar Chuanshan Biological Co., Ltd. is established in 1993. It is the only listed company specialized in seawater pearl oyster (Hepu Southern Pearl/Hepu Akoya pearl), algae, crustaceans and other special biological resources integrated development, processing in China. Its main business is pharmaceutical manufacturing, pharmaceutical distribution, medical technology services and molecular diagnosis and forensic industries. In 2022, the revenue of Gofar was 66 million USD.
Humanwell Healthcare (Group) Co., Ltd.
Humanwell Healthcare was founded in 1993. It has formed leadership or leading position in the segments of neurological drugs, steroid hormone drugs, Uyghur ethnic drugs, etc. In recent years, it has gradually expanded its business of American generics. It has formed a global R&D, registration, production and sales of the entire value chain of pharmaceuticals, exporting to 70 countries and regions worldwide. In 2022, the revenue of Humanwell Healthcare was 3.2 billion USD.
SCIMYTH Pharmaceutical Group
SCIMYTH Pharmaceutical Group is a large comprehensive group company with pharmaceutical as the mainstay, integrating herb cultivation, drug research and development, drug marketing and medical services covering pediatrics, gynecology, cardiovascular, respiratory, oncology, health care drugs and other fields. In 2022, its revenue reached 74 million USD. It is estimated to have a revenue of 700 billion USD in 2025.
Shandong Hanfang Pharmaceutical Co., Ltd.
Shangdong Hanfang Pharmaceutical Co., Ltd., founded in 2004, is a modern new traditional Chinese medicine enterprise integrating research and development, production and sales. it is a diversified pharmaceutical group that takes the traditional Chinese medicine industry as the leading role, and integrates biotechnology, medical devices, and traditional Chinese medicine derived cosmetics.
Luoxin Pharmaceutical Group Stock Co., Ltd.
Luoxin Pharmaceutical Group Stock Co., Ltd., founded in 1998, is a healthcare conglomerate that is engaged in pharmaceutical research and development, manufacture, sales, and healthcare service. The revenue of Luoxin in 2022 was 512 million USD.
Guangdong Zhongsheng Pharmaceutical Co., Ltd.
Guangdong Zhongsheng Pharmaceutical Co., Ltd. was founded in 1979. Based on the therapeutic fields of ophthalmology, cardiovascular, respiratory and digestive diseases, the company focuses on innovative drug research and development in specialty areas such as influenza, non-alcoholic steatohepatitis (NASH), ophthalmology, oncology and metabolic diseases, with pharmaceutical manufacturing as its core business. The company's main business covers the R&D, production and sales of Chinese traditional patent medicines, chemical medicines, Chinese medical materials and Chinese herbal slices, chemical API, and investment in ophthalmology-related industries. In 2022, the revenue of the company was 382 million USD.
Hunan Brilliance & Abundance Scientific Chinese Herbal Medicine Co., Ltd.
Hunan Brilliance & Abundance Scientific Chinese Herbal Medicine Co., Ltd., founded in 2002, is a high-tech modern pharmaceutical enterprise with Chinese medicine ultra-micro decoction pieces as the main product and pharmaceutical preparations and Chinese medicine extracts as the two wings.
Apeloa Pharmaceutical Co., Ltd.
Apeloa Pharmaceutical Co., Ltd., founded in 1989, has established good pharmaceutical R&D and manufacturing capabilities, forming three main business sectors of API, CDMO, and Finished Dosage Form (FDF). Apeloa has become a leading domestic company in special APIs.
As the major service provider of CDMO business in the global innovative drug industry chain, Apeloa has built a long-term strategic cooperative relationship with top domestic and foreign big pharma and biotech companies, and created well-known domestic brands such as "Baishixin" and "Tianliwei". Apeloa’s first high-end controlled-release generic drug has been recently launched in US market. It now has more than 1,000 employees in R&D. In 2022, Apeloa reached a revenue of 1.5 billion USD.
Hunan Heng Chang Pharmaceutical Group Co., Ltd.
Hunan Heng Chang Pharmaceutical Group Co., Ltd., founded in 2015, is a B2B pharmaceutical distribution enterprise focusing on serving small and medium-sized chain pharmacies, single pharmacies and primary health care institutions covering various fields such as Chinese patent medicines, western medicines, traditional Chinese medicine, pediatric medicine, health care products and medical devices. Up to now, the Group has operated more than 2,000 varieties, including more than 1,600 products under its own brand, and has more than 100,000 registered member customers, among which nearly 50,000 are active customers. In 2022, the revenue of Heng Chang was 700 billion USD.
Baotou Traditional Chinese Medicine Co., Ltd.
Baotou Traditional Chinese Medicine Co., Ltd., founded in 1974, is a modern TCM company that integrates R&D, manufacturing, sales and service. Its revenue is about 10 million USD.
Kamp Medicine Co., Ltd.
Kamp Medicine Co., Ltd., founded in 1991, is a unique pharmaceutical manufacturer produces both TCM and chemical drugs that treat digestive system diseases, cardiovascular and cerebrovascular diseases, liver and kidney diseases, anti-microbial infections, tonic and nutritional supplements, and APIs and other categories.
Guangxi Santo Pharmaceutical Co., Ltd.
Guangxi Santo Pharmaceutical Co., Ltd., founded in 1970, is specialized in Zhuang medicine. Its national exclusive products are "Jiubiying Stomachache Capsule", "Jiubiying Stomachache Tablet", "Xiao'er Xieshi Zhixie Powder", and the national protected variety of traditional Chinese medicine, "Terminalia Throat Tablet", which is the first medicine for treating chronic pharyngitis and chronic Tonsillitis in China. It has won the "Baihua Award" and other awards in Guangxi. In 2021, the revenue of Santo was 25.7 million USD.
Hunan Kangshou Pharmaceutical Co., Ltd.
Hunan Kangshou Pharmaceutical Co., Ltd., founded in 2003, owns 52 medicine permissions including 8 exclusive varieties of traditional Chinese medicine, such as Shengxuebao granules, Weixiangning granules, Maxing Xuanfei granules, Yinchen Wuling syrup, Guilu Yishen capsules, Chuanbei Pipa ointment, Shensu oral liquid, Jiangzhuo granules, etc.
Jiangxi Juwang Pharmaceutical Industry Co., Ltd.
Jiangxi Juwang Pharmaceutical Industry Co., Ltd., founded in 1969, is a pharmaceutical manufacturer specialized in products for heart disease, gynaecology and dietary supplements for blood glucose control. In 2021, the revenue of Juwang was 17 million USD.
Beijing Tcmages Pharmaceutical Co., Ltd.
Beijing Tcmages Pharmaceutical Co., Ltd. has been specialized in research and manufacturing of TCM formula granules for more than 20 years with its market share among the top three in China, and its products and services throughout the country covering more than 3,000 hospitals, and the products has been sold to more than 20 countries and regions in North America, Europe, Australia, etc. In 2022, the revenue of Tcmages was 370 million USD.
Guizhou Ruihe Pharmaceutical Co., Ltd.
Guizhou Ruihe Pharmaceutical Co., Ltd., founded in 1998, integrates the R&D, manufacturing and sales of TCM and chemical drugs covering small-capacity injections, granules, capsules, tablets, powder, etc. Among them, the specialized drug for liver disease treatment, "Shuganning Injection", is its flagship product.
Anhui CR Jinchan Pharmaceutical Co., Ltd. (Belongs to China Resources Sanjiu)
Anhui CR Jinchan Pharmaceutical Co., Ltd. is one of the four core production bases of China Resources Sanjiu Group, which carries the production tasks of two core products of China Resources Sanjiu, namely anti-tumor drugs and Chinese medicine granules. The Cinobufotalin series is a national Chinese medicine secret protected species, which is the first and exclusive production in China; its TCM formula granules are among the earliest pilot products approved by the state, and the first one to realize intelligent manufacturing in China.
Kangmei Pharmaceutical Co., Ltd.
Kangmei Pharmaceutical Co., Ltd., founded in 1997, has its business go through upper, middle, downstream of the traditional medicine industry from herb cultivation, trading to production and development and retails. At present, the company owns nearly 100 enterprises across the country covering the business of herb cultivation, herbal trading market, modern logistics center and industrial base, has constructed 11 modernized production bases for TCM decoction pieces and medicines, and manages more than 60% of the country's trade of the herbal market. In 2022, the revenue of Kangmei was 597 million USD.
Hunan Tianjicaotang Pharmaceutical Co., Ltd.
Hunan Tianjicaotang Pharmaceutical Co., Ltd. is a company that integrates pharmaceutical research and development, herb cultivation, pharmaceutical production and sales. The company's main series of products: clearing heat and detoxifying (Qingre Sanjie capsule, Yanning capsule, Chuanwang Xiaoyan capsule, etc.); Cardiovascular and cerebrovascular (Naodesheng pills, breviscapine tablets, etc.); Urinary products (compound Shilongtong capsule, compound Shiwei capsule, etc.).
Jiangxi Kingstone Unite Pharmaceutical Co., Ltd.
Jiangxi Kingstone Unite Pharmaceutical Co., Ltd., founded in 1978, is a pharmaceutical company that integrates herb cultivation, R&D, production and sales. The products are mainly used in pediatrics, gynecology, and cold and fever clearing medicine.
Shuguang Hospital Attached with Shanghai Chinese Medicine University
Shuguang Hospital Attached with Shanghai Chinese Medicine University is a century-old Class-A Grade-3 (top level in China) general hospital of Chinese Medicine in Shanghai. It is one of the Shanghai Top 10 general hospitals, and a national demonstration hospital of traditional Chinese medicine. The hospital offers 1,200 registered beds. It is with distinctive characteristics of Chinese Medicine and with prominent advantages. It has 3 key disciplines of the Ministry of Education: Orthopedics and Traumatology of TCM, Internal Medicine of TCM, and Chinese Pharmacy (Chinese Pharmaceutical Preparation and Clinical Pharmacology of TCM), 9 key disciplines of National Administration of Traditional Chinese Medicine, 6 key clinical specialties of National Health Commission, 14 key specialties. The Emergency Department of TCM is an emergency base of the National Administration of Traditional Chinese Medicine, the Preparation Room is a national base for traditional Chinese medicine preparation and dosage reform, and the Department of Neurology is a base for stroke prevention and treatment of National Health Commission.
Hunan Province Directly Affiliated TCM Hospital
Hunan Province Directly Affiliated TCM Hospital, founded in 1954, is a Class-A Grade-3 general hospital of Chinese Medicine, and national Top 100 Chinese Medicine hospital. It has 2,054 employees, and 1,800 beds available. Acupuncture and Moxibustion, Hepatology, Pulmonary Disease, Oncology, and Clinical Pharmacy are key TCM specialties of National Administration of Traditional Chinese Medicine. The strength of the hospital's urology, neurosurgery, general surgery, bariatric surgery, emergency medicine, obstetrics and gynecology is among the best in the province.
The First Hospital of Hunan University of Chinese Medicine
The First Hospital of Hunan University of Chinese Medicine, founded in 1963, is the clinical research base of TCM and national clinical teaching and training demonstration center of TCM. Its has a total construction area of 610,000 square meters and 1,800 registered beds. It receives more than 1.6 million outpatients and nearly 70,000 inpatients annually.
The Second Xiangya Hospital of Central South University
The Second Xiangya Hospital of Central South University, founded in 1958, ranks No. 13 in comprehensive strength of Chinese hospitals. It has 23 national key clinical disciplines. Its specialties such as Psychiatry, metabolic endocrinology, cardiovascular surgery, dermatology and venereal diseases, geriatrics, nephrology, clinical pharmacy, organ transplantation, and other specialties are among the top in the country. It once received 3.948 million outpatients and emergency visits, discharged 186,000 inpatients, and performed 146,000 operations annually as the highest case. In recent years, it has participated in the medical rescue of major domestic health emergencies for many times. During the COVID-19 prevention and control period, more than 600 people have been sent to Wuhan, Beijing, Xinjiang, West Africa and other places to fight the epidemic, ranked among the top in China.
The Second Hospital of Hunan University of Chinese Medicine (Hunan Chinese Medicine Hospital)
Founded in 1934, the Second Hospital of Hunan University of Chinese Medicine, also known as Hunan Chinese Medicine Hospital, is a national key provincial Class-A Grade-3 general hospital of Chinese medicine. It now has more than 1,200 employees, 1,156 beds available, 51 clinical and medical technology departments; 4 national key specialties: Proctology, Dermatology, Orthopedics, Gynecology; 3 key disciplines of National Administration of Traditional Chinese Medicine: TCM dermatology, TCM Proctology, TCM rehabilitation; 9 key specialties of National Administration of Traditional Chinese Medicine: Proctology, Dermatology, Orthopaedics, Gynecology, Encephalopathy, cardiovascular medicine, spleen and stomach diseases, Otolaryngology, Prevention and Health care of TCM.
The Orthopedics of Traditional Chinese Medicine Zhuzhou City
The Orthopedics of Traditional Chinese Medicine Zhuzhou City, founded in 1958, with "Shi's" traditional bone setting and medicine treatment technology as its academic heritage, is a Class-A Grade-3 bone injury specialty hospital. It ranked No. 62 among the Top 100 TCM hospital in TCM characteristic advantages and technological influence in 2020.